Search - tctmd.com

Displaying 1 - 20 of 38

Sort: Relevancy | Date

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

News Conference News ESC 2025

Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR

Michael O'Riordan

August 31, 2025

Presentation ESC 2025

BETAMI-DANBLOCK: Randomized Discontinuation of Beta-blockers After Myocardial Infarction in Patients Without Heart Failure

Presenter: Eva Prescott, Dan Atar

August 30, 2025

Presentation ESC 2025

Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction: REBOOT

Presenter: Borja Ibanez

August 30, 2025

News Conference News ESC 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

Caitlin E. Cox

August 30, 2025

News Conference News ESC 2025

Starting SGLT2 Inhibitors in the Hospital for Acute HF Gains Support

Todd Neale

August 30, 2025

News Conference News ESC 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Michael O'Riordan

August 30, 2025

News Conference News ESC 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Michael O'Riordan

August 29, 2025

News Opinion Editor's Corner ESC 2025

What’s Going to Be Hot at ESC Congress 2025?

Michael O'Riordan

August 25, 2025

News Conference News ESC 2024

ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients

Michael O'Riordan

August 30, 2024

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

L.A. McKeown

September 01, 2023

News ESC 2023

Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST

Michael O'Riordan

August 27, 2023

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

News Conference News ESC 2022

ARBs Halve Rate of Aortic Root Enlargement in Marfan: Meta-analysis

Shelley Wood

August 29, 2022

News Conference News ESC 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

Todd Neale

August 27, 2022

News Conference News ESC 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Michael O'Riordan

August 26, 2022

News Conference News ESC 2021

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

Yael L. Maxwell

September 03, 2021

News Conference News ESC 2021

PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer

Michael O'Riordan

August 30, 2021

News Conference News ESC 2021

New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT

Shelley Wood

August 28, 2021

News Conference News ESC 2020

Insights From a Deep Dive Into CV Risk Among Hospitalized COVID-19 Patients

Shelley Wood

September 04, 2020

Advertisement

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR

BETAMI-DANBLOCK: Randomized Discontinuation of Beta-blockers After Myocardial Infarction in Patients Without Heart Failure

Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction: REBOOT

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

Starting SGLT2 Inhibitors in the Hospital for Acute HF Gains Support

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

What’s Going to Be Hot at ESC Congress 2025?

ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST

CV Care Around Noncardiac Surgery: New ESC Guidelines

ARBs Halve Rate of Aortic Root Enlargement in Marfan: Meta-analysis

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

Polypill Bests Usual Care in Patients With Recent MI: SECURE

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer

New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT

Insights From a Deep Dive Into CV Risk Among Hospitalized COVID-19 Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content